1 unchanged sentence
Recent Sales of Unregistered Securities
−Removed: On July 1, 2020, we issued a warrant to purchase 8,444 shares of our common stock, or the Warrant, to a consultant in consideration for services provided by the consultant.
−Removed: The Warrant is exercisable at an exercise price of $2.92 per share and expires on July 1, 2025.
−Removed: The shares issuable upon exercise of the Warrant vest upon the consultant’s achievement of certain specified milestones.
−Removed: We offered and sold the Warrant pursuant to an exemption from registration under Section 4(a)(2) of the Securities Act.
−Removed: Except as stated in this quarterly report on Form 10-Q, we did not sell any securities that were not registered under the Securities Act during the three months ended September 30, 2020.
−Removed: Collaboration and License Agreement, dated as of October 22, 2020, by and between the Company and Ultragenyx Pharmaceutical Inc.
−Removed: Stock Purchase Agreement, dated as of October 22, 2020, by and between the Company and Ultragenyx Pharmaceutical Inc.
−Removed: Investor Agreement, dated as of October 22, 2020, by and between the Company and Ultragenyx Pharmaceutical Inc
−Removed: First Amendment, dated as of October 9, 2020, to the Exclusive Patent License by and between the Company and the University of Washington.
+Added: On March 4, 2021, we granted our Chief Legal Officer an option to purchase 325,000 shares of our common stock as an inducement to employment in accordance with Nasdaq Listing Rule 5635(c)(4).
+Added: No underwriters were involved in the foregoing issuance of securities.
+Added: The securities were issued pursuant to Section 4(a)(2) under the Securities Act of 1933, as amended, relating to transactions by an issuer not involving any public offering.
+Added: The recipient either received adequate information about us or had access, through other relationships, to such information.
+Added: The stock option is scheduled to become exercisable as to one-fourth of the shares underlying the option on each anniversary of our Chief Legal Officer’s start date, subject to the recipient’s continued service.
+Added: The option has an exercise price of $8.52 per share.
+Added: Consulting Agreement, dated as of January 4, 2021, by and between Solid Biosciences Inc.
Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 .
4 unchanged sentences
Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
−Removed: XBRL Instance Document
−Removed: XBRL Taxonomy Extension Schema Document
−Removed: XBRL Taxonomy Extension Calculation Linkbase Document
−Removed: XBRL Taxonomy Extension Definition Linkbase Document
−Removed: XBRL Taxonomy Extension Label Linkbase Document
−Removed: XBRL Taxonomy Extension Presentation Linkbase Document
+Added: Inline XBRL Instance Document
+Added: Inline XBRL Taxonomy Extension Schema Document
+Added: Inline XBRL Taxonomy Extension Calculation Linkbase Document
+Added: Inline XBRL Taxonomy Extension Definition Linkbase Document
+Added: Inline XBRL Taxonomy Extension Label Linkbase Document
+Added: Inline XBRL Taxonomy Extension Presentation Linkbase Document
Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)
−Removed: + Certain portions of this exhibit have been omitted because they are not material and would likely cause competitive harm to the Registrant if disclosed.
+Added: * Filed herewith.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Solid Biosciences Inc.
−Removed: November 5, 2020
/s/ Ilan Ganot
1 unchanged sentence
(Principal Executive Officer)
−Removed: November 5, 2020
−Removed: /s/ Jennifer Ziolkowski
−Removed: Jennifer Ziolkowski
−Removed: Chief Financial Officer
+Added: /s/ Stephen DiPalma
+Added: Stephen DiPalma
+Added: Interim Chief Financial Officer
(Principal Financial and Accounting Officer)
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.